Danny Liew

Danny Liew


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RORichard Ofori-Asenso
Richard Ofori-Asenso
KCKen L. Chin
Ken L. Chin
MMMohsen Mazidi
Mohsen Mazidi
EZElla Zomer
Ella Zomer
JIJenni Ilomaki
Jenni Ilomaki
DLDanny Liew
Danny Liew
The increasing average life expectancy has contributed to aging of the world’s population.1 By 2050, approximately 21.3% of the global population will be 60 years or older,2 up from 9.2% in 1990. Frailty, a clinical syndrome characterized by marked vulnerability due to decline in reserve and function across multiple physiologic systems, is common among older people.3,4 Frailty manifests as the inability to tolerate stressful events and has been associated with adverse outcomes, such as falls,5 delirium,6 institutionalization,7 incident disability,8 and mortality.9 Frailty is also an independent risk factor for poor outcomes after surgery (eg, prolonged hospitalizations, increased susceptibility to deconditioning, and faster functional decline)10 and is associated with higher health care use11 and corresponding costs.12 There is a growing interest among stakeholders in aged care to better understand the patterns and determinants of frailty.13

1 April 2015 in The Lancet
Verified
Journal Article
Closed access
PCPeter De Cruz
Peter De Cruz
MKMichael A Kamm
Michael A Kamm
AHAmy L Hamilton
Amy L Hamilton
KRKathryn J Ritchie
Kathryn J Ritchie
EKEfrosinia O Krejany
Efrosinia O Krejany
PDPaul V Desmond
Paul V Desmond

1 May 2015 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
EWEmily K. Wright
Emily K. Wright
MKMichael A Kamm
Michael A Kamm
PCPeter De Cruz
Peter De Cruz
AHAmy L. Hamilton
Amy L. Hamilton
KRKathryn J. Ritchie
Kathryn J. Ritchie
RGRichard Gearry
Richard Gearry

14 March 2005 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
TATai-Juan Aw
Tai-Juan Aw
SHSteven Joseph Haas
Steven Joseph Haas
DLDanny Liew
Danny Liew
HKHenry Krum
Henry Krum
Research from JAMA Internal Medicine — Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure

17 November 2003 in Medical Journal of Australia
Verified
Journal Article
Closed access
PDF file
DLDon Liew
Don Liew
DLDanny Liew
Danny Liew
MKMarcus P Kennedy
Marcus P Kennedy
Objective: To examine the association between emergency department length of stay (EDLOS) and inpatient length of stay (IPLOS). Design: Retrospective review of presentations and admissions data. Sett...

18 October 2013 in Brain
Verified
Journal Article
Open access
PDF file
TKTomas Kalincik
Tomas Kalincik
VVVino Vivek
Vino Vivek
VJVilija Jokubaitis
Vilija Jokubaitis
JLJeannette Lechner-Scott
Jeannette Lechner-Scott
MTMaria Trojano
Maria Trojano
HBHelmut Butzkueven
Helmut Butzkueven
The aim of this work was to evaluate sex differences in the incidence of multiple sclerosis relapses; assess the relationship between sex and primary progressive disease course; and compare effects of age and disease duration on relapse incidence. Annualized relapse rates were calculated using the MSBase registry. Patients with incomplete data or <1 year of follow-up were excluded. Patients with primary progressive multiple sclerosis were only included in the sex ratio analysis. Relapse incidences over 40 years of multiple sclerosis or 70 years of age were compared between females and males with Andersen-Gill and Tweedie models. Female-to-male ratios stratified by annual relapse count were evaluated across disease duration and patient age and compared between relapse-onset and primary progressive multiple sclerosis. The study cohort consisted of 11 570 eligible patients with relapse-onset and 881 patients with primary progressive multiple sclerosis. Among the relapse-onset patients (82 552 patient-years), 48 362 relapses were recorded. Relapse frequency was 17.7% higher in females compared with males. Within the initial 5 years, the female-to-male ratio increased from 2.3:1 to 3.3:1 in patients with 0 versus ≥4 relapses per year, respectively. The magnitude of this sex effect increased at longer disease duration and older age (P < 10−12). However, the female-to-male ratio in patients with relapse-onset multiple sclerosis and zero relapses in any given year was double that of the patients with primary progressive multiple sclerosis. Patient age was a more important determinant of decline in relapse incidence than disease duration (P < 10−12). Females are predisposed to higher relapse activity than males. However, this difference does not explain the markedly lower female-to-male sex ratio in primary progressive multiple sclerosis. Decline in relapse activity over time is more closely related to patient age than disease duration.